<DOC>
	<DOCNO>NCT00143689</DOCNO>
	<brief_summary>This study compare nucleoside reverse transcriptase inhibitor-sparing ( NRTI-sparing ) regimen ( Kaletra + nevirapine ) two nucleoside reverse transcriptase inhibitor-based regimen ( Combivir + nevirapine Combivir + Kaletra ) . Participants randomly assign receive one follow drug combination : - lopinavir/ritonavir ( Kaletra ) nevirapine ( Viramune ) twice day ; - Combivir ( Zidovudine ( AZT ) plus lamivudine ( 3TC ) ) nevirapine twice day ; - Combivir lopinavir/ritonavir twice day .</brief_summary>
	<brief_title>NRTI-Sparing Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Be HIVpositive Be least18 year age Have viral load 5 000 copies/ml Be likely comply study protocol Agree take , duration study , drug contraindicate study drug Agree take medication , include overthecounter medicine , alcohol , street drug without knowledge permission principal investigator Have ever receive antiretroviral therapy Pregnancy breastfeed Have abnormal laboratory test ( see investigator ) Have receive investigational drug within 30 day study drug administration Be receive systemic chemotherapy Have acute illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>